Funding support: This manuscript was sponsored by Allergan, Inc., Irvine, CA, USA.
The Evolution of Chronic Migraine: Classification and Nomenclature
Version of Record online: 28 APR 2009
© 2009 the Authors. Journal compilation © 2009 American Headache Society
Headache: The Journal of Head and Face Pain
Volume 49, Issue 8, pages 1206–1213, September 2009
How to Cite
Manack, A., Turkel, C. and Silberstein, S. (2009), The Evolution of Chronic Migraine: Classification and Nomenclature. Headache: The Journal of Head and Face Pain, 49: 1206–1213. doi: 10.1111/j.1526-4610.2009.01432.x
Conflict of Interest: Drs. Turkel and Manack are employees of Allergan, Inc. Dr. Silberstein has proprietary interest (Speaker/Advisory Board/Grants) in the following commercial health care-related businesses: Abbott, Advanced Bionics, Advanced NeurModulation System, AGA, Allergan, AstraZeneca, Endo, GSK, Lilly, Medtronic, Merck, Ortho-McNeil, Pfizer, Pozen, ProEthic, Valeant, Vernalis.
- Issue online: 26 AUG 2009
- Version of Record online: 28 APR 2009
- Accepted for publication February 19, 2009.
- chronic migraine;
After nearly 3 decades of debate, the headache community still lacks globally accepted criteria for chronic migraine. This review summarizes the evolution of chronic migraine nomenclature and criteria. We concluded that although there are discrepancies in the currently proposed criteria, there is a significant amount of overlap with previously used classifications such that they all appear to describe the same subset of highly burdened migraine patients. In order to continue to understand the natural history of chronic migraine, address the unmet medical need, and develop effective therapies, field experts and physicians must have a classification that is well understood and accepted by the broader clinical community. It is our view that of the currently established classifications, the Silberstein and Lipton revised criteria for transformed migraine are the most applicable to daily clinical practice and field research.